← Leaderboards

James Robert Fuchs

Ohio State University

Google Scholar ↗PubMed ↗ORCID ↗

$4,283,906

Attributed

$8,488,144

Total exposure

8

Grants

5

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.5M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$12,935,264 · 9

By mechanism

R01$6,298,159 · 3

P01$6,120,061 · 4

R21$429,000 · 1

F32$88,044 · 1

Top collaborators

Most similar at Ohio State University

Same institution · by research overlap

Michael R Grever$17,739,693
Claudia Turro$927,409
Ramana V Davuluri$7,215,061
Philip R.o. Payne$8,781,842
Xia Ning$3,689,500

Others in their field

Top investigators on “Biological”

David Heimbrook · Leidos Biomedical Research, Inc.$731,505,112
Sonia M Thomas · Research Triangle Institute$700,865,642
David Divins · Consortium For Ocean Leadership, Inc$609,772,544
Lawrence Corey · Fred Hutchinson Cancer Center$543,202,300
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$480,487,534
Tracy L Nolen · Research Triangle Institute$474,487,152

Research focus

BiologicalPharmaceutical ChemistryCellsLeadBindingPharmaceutical PreparationsProteinsGenerationsStructure-Activity RelationshipEvaluationModificationIn VitroDoseChicagoInsightIn VivoComprehensive Cancer CenterIllinoisProgramsScale UpDrug KineticsOhioAntineoplastic AgentsNorth Carolina

Grant awards (28)

Discovery of Anticancer Agents of Diverse Natural Origin$1,640,056

P01 · FY2025 · CA

Role of HIV-1 integrase in virion morphogenesis and its targeting by allosteric integrase inhibitors$802,476

R01 · FY2025 · AI

Generative AI for retrosynthesis libraries$330,004

R01 · FY2025 · LM

Core 2: Medicinal Chemistry and Pharmacokinetics Core$258,628

P01 · FY2025 · CA · contact PI

Discovery of Anticancer Agents of Diverse Natural Origin$1,367,748

P01 · FY2024 · CA

Role of HIV-1 integrase in virion morphogenesis and its targeting by allosteric integrase inhibitors$847,141

R01 · FY2024 · AI

Ultra-potent HIV capsid inhibitors$792,015

R01 · FY2024 · AI

Generative AI for retrosynthesis libraries$330,713

R01 · FY2024 · LM

Core 2: Medicinal Chemistry and Pharmacokinetics Core$143,268

P01 · FY2024 · CA · contact PI

Discovery of Anticancer Agents of Diverse Natural Origin$1,439,316

P01 · FY2023 · CA

Ultra-potent HIV capsid inhibitors$792,015

R01 · FY2023 · AI

Core 2: Medicinal Chemistry and Pharmacokinetics Core$145,498

P01 · FY2023 · CA · contact PI

Ultra-potent HIV capsid inhibitors$792,015

R01 · FY2022 · AI

Core 2: Medicinal Chemistry and Pharmacokinetics Core$129,370

P01 · FY2022 · CA · contact PI

Ultra-potent HIV capsid inhibitors$792,015

R01 · FY2021 · AI

Core 2: Medicinal Chemistry and Pharmacokinetics Core$150,813

P01 · FY2021 · CA · contact PI

Ultra-potent HIV capsid inhibitors$819,765

R01 · FY2020 · AI

Core 2: Medicinal Chemistry and Pharmacokinetics Core$156,961

P01 · FY2020 · CA · contact PI

Development of Novel Scaffolds as Tools for Allosteric HIV-1 Integrase Inhibition$234,000

R21 · FY2019 · AI · contact PI

Development of Novel Scaffolds as Tools for Allosteric HIV-1 Integrase Inhibition$195,000

R21 · FY2018 · AI · contact PI

Medicinal Chemistry and Pharmacokinetics Core$131,274

P01 · FY2018 · CA · contact PI

Medicinal Chemistry and Pharmacokinetics Core$26,515

P01 · FY2018 · CA · contact PI

Medicinal Chemistry and Pharmacokinetics Core$131,274

P01 · FY2017 · CA · contact PI

Medicinal Chemistry and Pharmacokinetics Core$131,274

P01 · FY2016 · CA · contact PI

Medicinal Chemistry and Pharmacokinetics Core$132,581

P01 · FY2015 · CA · contact PI

Medicinal Chemistry and Pharmacokinetics Core$135,485

P01 · FY2014 · CA · contact PI

Synthesis of Abyssomicin C and Novel Analogs$45,976

F32 · FY2006 · AI · contact PI

Synthesis of Abyssomicin C and Novel Analogs$42,068

F32 · FY2005 · AI